Clinical Report: Systematic Review of CAR T-Cell Therapy for Refractory SLE
Overview
This systematic review evaluates CAR-based cellular therapy for refractory systemic lupus erythematosus (SLE). The analysis reveals a predominantly female cohort with significant renal involvement and varying endpoint evaluability.
Background
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can lead to severe multi-organ damage, particularly in patients with refractory forms. Current treatment options often fail to achieve durable remission, especially in cases involving lupus nephritis. CAR T-cell therapy represents a novel approach in these challenging cases.
Data Highlights
Outcome
Patients Evaluated
Response
Clinical response
45
100%
DORIS remission
15
86.7%
SLE Responder Index-4 response
20
100%
Renal improvement
5
100%
Drug-free remission
58
48.3%
Key Findings
Twenty-one independent study units with 114 patients were included in the review.
The cohort was predominantly female (87.7%) with a median age of 32 years.
Renal involvement was present in 78.1% of patients.
Clinical response was documented in all evaluable patients (45/45).
Cytokine release syndrome was mostly low grade, with severe toxicities occurring in select cases.
Endpoint evaluability varied significantly across studies, highlighting the need for standardized reporting.
Clinical Implications
The findings highlight the variability in endpoint evaluability and the early stage of evidence.
Conclusion
Current evidence is limited and requires further investigation through well-designed prospective studies.
The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.
